{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wislez M"],"funding":["AstraZeneca","Intergroupe Francophone de Cancérologie Thoracique"],"pagination":["e005636"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9594538"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(10)"],"pubmed_abstract":["<h4>Background</h4>The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).<h4>Methods</h4>In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate. Secondary endpoints included tumor response rate, major histopathological response (MPR: ≤10% remaining viable tumor cells), disease-free survival (DFS), overall survival (OS), durvalumab-related safety, and 90-day postoperative mortality (NCT03030131).<h4>Results</h4>Forty-six patients were eligible (median age 60.9 years); 67"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)."],"pmcid":["PMC9594538"],"funding_grant_id":["ESR-15-11017","IFCT-1601"],"pubmed_authors":["Damotte D","Westeel V","Lavole A","Assouad J","Molinier O","Brouchet L","Carre O","Milleron B","Massiani MA","Dubos-Arvis C","Mazieres J","Egenod T","Caliandro R","Morin F","Zalcman G","Langlais A","Antoine M","Jeannin G","Wislez M","Le Pimpec Barthes F"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).","description":"<h4>Background</h4>The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).<h4>Methods</h4>In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate. Secondary endpoints included tumor response rate, major histopathological response (MPR: ≤10% remaining viable tumor cells), disease-free survival (DFS), overall survival (OS), durvalumab-related safety, and 90-day postoperative mortality (NCT03030131).<h4>Results</h4>Forty-six patients were eligible (median age 60.9 years); 67","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-07-14T17:17:35.417Z","creation":"2026-06-21T03:12:40.247Z"},"accession":"S-EPMC9594538","cross_references":{"pubmed":["36270733"],"doi":["10.1136/jitc-2022-005636"]}}